Unicorn Biotechnologies develops bioreactors and systems engineered for growing animal cells at scale rather than repurposing hardware built for yeast, bacteria or vaccine production. Its core product approach emphasizes modularity — many smaller systems operating in parallel — to simplify control and scaling. The company is building end-to-end automation with built-in sensing, machine learning and industrial automation so operators can run systems without specialized Ph.D. expertise. Unicorn is currently at prototype stage and is using recent funding to move toward a commercial product. The startup has hired staff with part of the new capital and aims to deliver a proof-of-concept scale machine capable of producing kilograms of cells by the end of the year. Pilot projects with partners are expected around that time or in early 2023, and the company intends to enable other cultivated-meat firms rather than produce meat itself.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2022